Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Search
Search results
Opus Genetics completes enrolment in phase 3 trial of OPGx-LCA5
Opus Genetics has completed enrolment in its registrational phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for LCA5-related Leber Congenital Amaurosis (LCA).
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Meet our supporters: Ian Shorthose
Whether you're an expert runner, or a rebel *with* a cause, there's no better experience than the London Marathon!
Meet a Researcher: Stéphanie Cornelis and Mubeen Khan
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Atsena Therapeutics present positive clinical data for LCA1 gene therapy program
Astena Theraputics' investigational gene therapy, ATSN-101, has shown promising long-term results in an early clinical trial for LCA1, a sever inherited retinal disease caused by mutations in the GUCY2D gene.
New mechanism of disease discovered for Retinitis Pigmentosa
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Retina-on-a-chip: the tiny technology offering big hope for inherited sight loss
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.